Alexion Pharm Inc (ALXN) Stock Price & Overview
NASDAQ:ALXN
Current stock price
The current stock price of ALXN is 182.5 null. Today ALXN is up by 1.7%. In the past month the price increased by 1.02%. In the past year, price increased by 79.82%.
ALXN Key Statistics
- Market Cap
- 40.336B
- P/E
- 14.22
- Fwd P/E
- 12.48
- EPS (TTM)
- 12.83
- Dividend Yield
- N/A
ALXN Stock Performance
ALXN Stock Chart
ALXN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ALXN. When comparing the yearly performance of all stocks, ALXN is one of the better performing stocks in the market, outperforming 83.7% of all stocks.
ALXN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ALXN. ALXN has an average financial health and profitability rating.
ALXN Earnings
ALXN Forecast & Estimates
13 analysts have analysed ALXN and the average price target is 180.9 null. This implies a price decrease of -0.87% is expected in the next year compared to the current price of 182.5.
For the next year, analysts expect an EPS growth of 9.86% and a revenue growth 12.08% for ALXN
ALXN Groups
Sector & Classification
ALXN Financial Highlights
Over the last trailing twelve months ALXN reported a non-GAAP Earnings per Share(EPS) of 12.83. The EPS increased by 12.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.89% | ||
| ROA | 3.66% | ||
| ROE | 5.48% | ||
| Debt/Equity | 0.19 |
ALXN Ownership
ALXN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.11 | 370.255B | ||
| AMGN | AMGEN INC | 15.28 | 188.011B | ||
| GILD | GILEAD SCIENCES INC | 15.19 | 166.661B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.34 | 110.013B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.78 | 77.991B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.53 | 42.088B | ||
| INSM | INSMED INC | N/A | 31.319B | ||
| BIIB | BIOGEN INC | 11.43 | 26.98B | ||
| NTRA | NATERA INC | N/A | 25.887B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.5 | 22.916B | ||
| MRNA | MODERNA INC | N/A | 19.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.333B | ||
| INCY | INCYTE CORP | 11.79 | 17.971B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ALXN
Company Profile
Alexion Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 3,837 full-time employees. The firm is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.
Company Info
IPO: 1996-02-01
Alexion Pharm Inc
121 Seaport Blvd
Boston MASSACHUSETTS 02210 US
CEO: Ludwig N. Hantson
Employees: 3837
Phone: 14752302596.0
Alexion Pharm Inc / ALXN FAQ
Can you describe the business of Alexion Pharm Inc?
Alexion Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 3,837 full-time employees. The firm is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.
What is the stock price of Alexion Pharm Inc today?
The current stock price of ALXN is 182.5 null. The price increased by 1.7% in the last trading session.
Does ALXN stock pay dividends?
ALXN does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALXN stock?
ALXN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What do analysts say about Alexion Pharm Inc (ALXN) stock?
13 analysts have analysed ALXN and the average price target is 180.9 null. This implies a price decrease of -0.87% is expected in the next year compared to the current price of 182.5.
What is the Price/Earnings (PE) ratio of Alexion Pharm Inc (ALXN)?
The PE ratio for Alexion Pharm Inc (ALXN) is 14.22. This is based on the reported non-GAAP earnings per share of 12.83 and the current share price of 182.5 null.
Can you provide the market cap for Alexion Pharm Inc?
Alexion Pharm Inc (ALXN) has a market capitalization of 40.34B null. This makes ALXN a Large Cap stock.